Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma

In the primary analysis of the phase III COLUMBA study, daratumumab by subcutaneous administration (DARA SC) demonstrated non-inferiority to intravenous administration (DARA IV) for relapsed or refractory multiple myeloma (RRMM). Here, we report the final analysis of efficacy and safety from COLUMB...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Saad Z. Usmani, Hareth Nahi, Wojciech Legiec, Sebastian Grosicki, Vladimir Vorobyev, Ivan Spicka, Vania Hungria, Sibirina Korenkova, Nizar J. Bahlis, Max Flogegard, Joan Bladé, Philippe Moreau, Martin Kaiser, Shinsuke Iida, Jacob Laubach, Hila Magen, Michele Cavo, Cyrille Hulin, Darrell White, Valerio De Stefano, Kristen Lantz, Lisa O’Rourke, Christoph Heuck, Maria Delioukina, Xiang Qin, Ivo Nnane, Ming Qi, Maria-Victoria Mateos
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Ferrata Storti Foundation 2022-03-01
coleção:	Haematologica
Acesso em linha:	https://haematologica.org/article/view/10587
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!